Sun Pharma Agrees All-Cash Acquisition of Organon
The acquisition is expected to create a global powerhouse in women’s health, biosimilars and branded generics with operations in 150 countries, and is set to close in early 2027 pending approvals.
Specialty generics company, Sun Pharma, has agreed to buy Organon, a global healthcare company focused on women’s health and other established medicines, in an all-cash deal valued at USD 11.75 billion. Organon stockholders will receive USD 14.00 per share, with both companies expecting the transaction to close in early 2027 — subject to regulatory approvals and a vote by Organon shareholders (1).
The proposed acquisition of Organon aligns with Sun Pharma’s strategy to grow its innovative medicines business and strengthen its established brands, branded generics, and biosimilars portfolios. Organon’s portfolio, international footprint, and stakeholder relationships will complement Sun Pharma’s strengths, adding scale to its global operations and supporting long-term value creation, with the new combined company becoming a top 10 global player in biosimilars.
“This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives,” said Dilip Shanghvi, Executive Chairman of Sun Pharma, in a company press release (1). “Organon’s portfolio, capabilities, and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.”
Kirti Ganorkar, Managing Director of Sun Pharma, added, in the press release (1): “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products. In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years.”
“Following a comprehensive review of strategic alternatives, our Board determined that this all‑cash transaction offers compelling and immediate value to Organon stockholders,” commented Carrie Cox, Executive Chair of Organon, in the press release (1). We believe Sun Pharma is well positioned to support Organon’s businesses, employees and patients globally, and to further advance our commitment to delivering impactful medicines and solutions.”
The deal adds to a period of consolidation in global pharmaceuticals, as large drugmakers continue to seek growth through acquisitions, portfolio expansion, and geographic diversification. Sun Pharma said it plans to finance the acquisition with available cash and committed bank debt. If completed, the combined entity would generate USD 12.4 billion in revenue, rank top-three globally in women’s health, become the seventh largest biosimilars player, and operate in 150 countries to significantly boost Sun Pharma’s presence in developed markets (1).
Reference
Sun Pharma. Sun Pharma signs Definitive Agreement to Acquire Organon. Press release, April 27, 2026.